Pharmala Biotech HoldingsMDXXF +7.74%35 Current Ratio is 1.42 as of Feb. 2026, which is 1% below its 10-year median of 1.44. GuruFocus rates MDXXF with a GF Score™ of 35/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Pharmala Biotech Holdings ranks worse than 77.23% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pharmala Biotech Holdings's current ratio for the quarter that ended in Feb. 2026 was 1.42.
Pharmala Biotech Holdings has a current ratio of 1.42. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pharmala Biotech Holdings's Current Ratio or its related term are showing as below:
MDXXF'
s Current Ratio Range Over the Past 10 Years
Min: 0.6 Med: 1.44 Max: 18.35
Current: 1.42
During the past 5 years, Pharmala Biotech Holdings's highest Current Ratio was 18.35. The lowest was 0.60. And the median was 1.44.
MDXXF's Current Ratio is ranked worse than 77.23% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs MDXXF: 1.42
Pharmala Biotech Holdings (OTCPK:MDXXF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pharmala Biotech Holdings Current Ratio Related Terms
Pharmala Biotech Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXXF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Pharmala Biotech Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmala Biotech Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pharmala Biotech Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmala Biotech Holdings (MDXXF) has a Current Ratio of 1.42 as of Feb. 2026. This is near median its historical median of 1.44. Over the past decade, Pharmala Biotech Holdings' Current Ratio has ranged from 0.60 to 18.35. According to the industry distribution chart, Pharmala Biotech Holdings ranks #1089 out of 1410 companies in the Biotechnology industry, placing it in the top 77.2%.
Is Pharmala Biotech Holdings' Current Ratio too high?
Pharmala Biotech Holdings' current Current Ratio of 1.42 is near median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 18.35. The Biotechnology industry median Current Ratio is 3.89. Pharmala Biotech Holdings' value of 1.42 is 63.5% below this industry median. Based on the distribution chart, Pharmala Biotech Holdings ranks #1089 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmala Biotech Holdings ranks #1089 out of 1410 companies for Current Ratio. This places Pharmala Biotech Holdings in the lower half of its industry. The industry median Current Ratio is 3.89. Pharmala Biotech Holdings' value of 1.42 is 63.5% below this benchmark. Historically, Pharmala Biotech Holdings' own Current Ratio has ranged from 0.60 to 18.35 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 3.89, Pharmala Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmala Biotech Holdings's current Current Ratio of 1.42 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmala Biotech Holdings's current Current Ratio is 1.42, which is near median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current Current Ratio is 1.42, which is near median its 10-year median of 1.44 and 63.5% below the Biotechnology industry median of 3.89. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Current Ratio is 1.42 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued.
The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15.
GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.
Key valuation signals for MDXXF:
Current Ratio: 1.42 (near median its 10-year median of 1.44)
GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
Industry Position: 63.5% below the Biotechnology median (#1089 of 1410)
No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score
Get the complete analysis for MDXXF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXXF has been successfully added to your 
